Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort studyBNT162b2 3차 백신 접종 후 면역 저하 및 건강한 2차 백신 대비 강력한 항체 반응, 전향적 종단 코호트 연구Observational Study Published on 2022-06-262022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] administration age antibody Antibody Response BNT162b2 BNT162b2 vaccine booster calculated conducted COVID-19 dose elicited evaluate groups healthy individuals humoral Humoral response IgG IgG titer Immunocompromised immunocompromised individuals longitudinal cohort study participant Participants prospective observational study robust SARS-CoV-2 second dose Seroconversion seronegative seropositive spike Spike IgG titer subset the antibody response Third vaccine dose. vaccine dose were measured women [DOI] 10.1016/j.vaccine.2022.05.051 PMC 바로가기 [Article Type] Observational Study
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccineesCOVID-19 mRNA 백신에 있는 Omicron BA.1 및 BA.2 중화 항체의 해부학Article Published on 2022-06-132022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Administered antibody BNT162b2 BNT162b2 mRNA vaccine class conserved COVID-19 COVID-19 pandemic cross-neutralize cross-neutralizing antibodies cross-neutralizing antibody cross-protection Donor Effect elicited epitope Epitopes Evidence germlines IGHV1-58 IGHV1-69 IGHV2-5 mitigate molecular molecular basis mRNA mRNA vaccine NAb NAbs neutralization neutralize Neutralizing antibodies neutralizing antibody neutralizing monoclonal antibodies neutralizing monoclonal antibody not neutralize NTD omicron other coronaviruses predominant question RBD Receptor binding domain recognize Region S protein SARS-CoV-1 SARS-CoV-1 virus SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 vaccines seronegative seropositive Spike protein tested the S protein the SARS-CoV-2 vaccination Vaccine design vaccinee Vaccines variants variety virus Wuhan [DOI] 10.1038/s41467-022-31115-8 PMC 바로가기 [Article Type] Article
Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers의료 및 대학 근로자에서 SARS-CoV-2 항체의 존재 및 장기간 지속성에 대한 예측 요인Article Published on 2022-06-132022-09-12 Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome Analysis Anosmia antibodies Cohort collected Contact coronavirus correlated cough COVID-19 early phase Factor Fever handling healthcare Hematological malignancy higher risk hospital immunization immunodeficiency initial medication myalgia nasal pandemic participant Patient patient group patients persistence respiratory specimens risk risk factor SARS-CoV-2 SARS-CoV-2 antibody seronegative Seroprevalence Severe COVID-19 Infection solid tumor subject sustained Symptom Symptoms tested Transmission variable while with COVID-19 [DOI] 10.1038/s41598-022-13450-4 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial6~17세 어린이 대상 ChAdOx1 nCoV-19(AZD1222) 백신의 안전성 및 면역원성: 2상 단일 맹검, 무작위, 대조 시험인 COV006의 예비 보고서Clinical Trial Published on 2022-06-112022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] 95% CI administration Adults adverse event adverse events age All participants anti-SARS-CoV-2 IgG antibody Antibody titre antibody titres arbitrary unit assigned AstraZeneca AZD1222 baseline capsular Cellular responses ChAdOx1 ChAdOx1 nCoV-19 children chronic respiratory conditions Concentration Controlled trial COVID-19 COVID-19 vaccine COVID-19 vaccines Cutoff Department dose doses Efficacy enrolled Fever first dose first vaccination four group four groups geometric geometric mean geometric mean ratios Geometric means group half-maximal inhibitory concentration Humoral response humoral responses immune response immune responses immunogenic immunogenicity in some intramuscular dose introduced investigators ISRCTN Laboratory laboratory-confirmed Laboratory-confirmed COVID-19 Local nucleocapsid protein Pain and tenderness participant Participants peaked Phase 2 phase 3 study preliminary report Primary outcome prime and boost raised randomised Randomly receive receiving recruitment Registered remained reported resolved respiratory response Safety safety population SARS-CoV-2 second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events seronegative seronegative participant seronegative participants seropositive serostatus single-blind stratified study drug study groups tenderness Tolerability treatment allocation Trial vaccination Vaccine Viral viral particle were recorded [DOI] 10.1016/S0140-6736(22)00770-X PMC 바로가기 [Article Type] Clinical Trial
Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study3차 1차 SARS-CoV-2 예방접종 후 혈청유병률 증가 및 항체 반응 개선: COV-AD 연구의 업데이트Article Published on 2022-06-022022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Anti-spike antibody Antibody Response AstraZeneca B.1.1.529 cellular immunity cellular response ChAdOx1 ChAdOx1 nCoV-19 cohort of patient COVID-19 cross-reactive CVID deficiency detectable determine dose ELISA ELISpot assays ENhance enrolled glycoprotein healthy control healthy controls heterogeneous heterologous vaccine humoral Humoral immunity immunodeficiency immunogenicity Improved Inborn errors inborn errors of immunity Increased individual initial magnitude mounted neutralisation neutralising no differences participant Pfizer Primary Immunodeficiency remained response SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary antibody secondary immunodeficiency Seroconversion serological response seronegative Seroprevalence significantly increased significantly lower significantly more Support T cell T cell response the antibody response the SARS-CoV-2 These data vaccination Vaccine vaccine dose vaccine doses variant widespread [DOI] 10.3389/fimmu.2022.912571 PMC 바로가기 [Article Type] Article
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine재조합 식물 기반 면역증강제 코로나19 백신의 효능 및 안전성Clinical Trial Published on 2022-06-022022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, 치료제, [키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant adverse event age Analysis AS03 assigned baseline candidate vaccine caused conducted coronavirus coronavirus disease Coronavirus disease 2019 CoVLP CoVLP+AS03 determine disease dose effective Efficacy Factor FIVE incidence injection intention-to-treat intention-to-treat population Intramuscular injection Local median age Median viral load Medicago Mild moderate occurred participant Participants participated Particle performed Phase 3 Placebo placebo group placebo-controlled trial plant plants polymerase post-hoc analysis prefusion produced Randomized receive recombinant respiratory Safety SARS-CoV-2 sequenced Sequencing seronegative severe acute respiratory syndrome Coronavirus Severe case Spectrum spike glycoprotein symptomatic symptomatic COVID-19 symptomatic infection System systemic adverse event systemic adverse events the median the placebo group the vaccine Trial two group two groups Vaccine vaccine efficacy vaccine group variant variants Viral Viral load viral sample Volunteer [DOI] 10.1056/NEJMoa2201300 PMC 바로가기 [Article Type] Clinical Trial
Seroprevalence of SARS-CoV-2 IgG antibody among healthy blood donors: a single centre study건강한 헌혈자 중 SARS-CoV-2 IgG 항체의 혈청 유병률: 단일 센터 연구Article Published on 2022-06-012022-09-11 Journal: Transfusion and apheresis science : official journ [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] acute respiratory syndrome addition age Analysis antibody association Blood blood donor Blood donors Blood Group causative agent chemiluminescence Community Corona virus COVID-19 cross-sectional cross-sectional study detect Donor donors enrolled global pandemic healthy healthy blood donor healthy blood donors IgG antibody indication Infection majority Off Prevalence reactive respiratory SARS- CoV-2 SARS-CoV SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 IgG antibody SARS-COV-2 infection screened seronegative seropositive Seropositivity Seroprevalence serum sample serum samples Severe acute respiratory syndrome Severe Acute Respiratory Syndrome Corona Virus signal statistically significant transmitted virus was used Whole blood [DOI] 10.1016/j.transci.2021.103338 PMC 바로가기 [Article Type] Article
Quantifying Risk for SARS-CoV-2 Infection Among Nursing Home Workers for the 2020-2021 Winter Surge of the COVID-19 Pandemic in Georgia, USA미국 조지아주 코로나19 팬데믹의 2020-2021년 겨울 급증에 대한 요양원 근로자의 SARS-CoV-2 감염 위험 정량화Article Published on 2022-06-012022-09-11 Journal: Journal of the American Medical Directors Associat [Category] COVID19(2023년), SARS, 치료법, [키워드] 95% CI 95% CIs adjusted odds ratio adjusted odds ratios antibody assistant Community COVID-19 COVID-19 vaccination Critical defined effort eligible estimate Evidence evidence of facility home incidence increased risk Infection Infection prevention interval multivariable analysis multivariable logistic regression nucleocapsid protein Nurse Nurses Nursing nursing home nursing homes occupational Occupational safety pandemic provided reported risk Risk factors SARS-CoV-2 SARS-COV-2 infection Seroconversion serologic testing serology seronegative setting significantly higher specimen Spike protein study cohort The United States United States USA vaccination Vaccine Winter worker [DOI] 10.1016/j.jamda.2022.02.014 PMC 바로가기 [Article Type] Article
Cytokine response over the course of COVID-19 infection in pregnant women임산부의 코로나19 감염 과정에서 사이토카인 반응Article Published on 2022-06-012022-09-12 Journal: Cytokine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Affect Clinical severity cohorts conducted controls coronavirus disease correlated Course COVID-19 COVID-19 infection COVID-19 symptom cytokine level cytokine profile defined elevated ELISA G-CSF HGF IgG antibodies IgM and IgG IgM seroconversion IL-18 IL-8 Infection infections interferon interleukin IP-10 material NIH Patient patients positive positive RT-PCR Pregnancy pregnant pregnant women profile progression remained returned RT-PCR SARS-CoV-2 serology seronegative seropositive severe disease severity significantly specific IgM stratified tested uninfected Vital were measured [DOI] 10.1016/j.cyto.2022.155894 PMC 바로가기 [Article Type] Article
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies항암치료를 받는 환자의 코로나19 백신접종에 대한 항체 및 T세포 반응Article Published on 2022-06-012022-09-11 Journal: Journal for immunotherapy of cancer [Category] COVID19(2023년), MERS, SARS, 바이오마커, 변종, 진단, 치료기술, 치료제, [키워드] active treatment adrenal crisis Adrenal insufficiency Affect Anti-CD20 antibodies Anti-CD20 antibody Anti-viral antibodies antibody antibody formation Antibody titer Antibody titers Anticancer therapy B cells B-cell B.1.617.2 blockade Cancer CD4 CD8 Cell cellular Chemoimmunotherapy Chemotherapy Corticosteroids COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccination COVID-19 vaccinations COVID-19 vaccine trials cross-reactive cytokine detectable develop dose doses effector cells Endocrine expressed follicular generate healthy donor healthy donors helper cells Humoral response hypoadrenalism Hypothesis IgG antibody titer immune Immunocompromised immunogenic immunogenicity immunogenicity, vaccine Immunotherapy intracellular cytokine staining Lymphocytes mRNA vaccine Multiple myeloma Myeloma n=36 no differences oncology patients Participants Patient Patients with cancer PD-1 peptide peptides Phase 3 profile Prophylactic RBD reactivity receiving Receptor binding domain Safe seronegative seronegative patient Side effect solid tumors spike Spike protein steroid Steroids Stress symptomatic T cell T cell response T cell responses T cells T follicular helper cells T-lymphocytes targeted therapy the SARS-CoV-2 therapy Treatment treatment groups tumors Two patient two patients vaccination Vaccinations Vaccine variant spike was measured were assessed were excluded wild-type WT spike [DOI] 10.1136/jitc-2022-004766 PMC 바로가기 [Article Type] Article